Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ESMO
Pharma
BMS details Krazati confirmatory fail in colorectal cancer
BMS has detailed a phase 3 flop for KRAS inhibitor Krazati's smaller-opportunity accelerated FDA approval in colorectal cancer.
Fraiser Kansteiner
Jul 7, 2026 10:46am
Novartis, Daiichi, AZ shine in ESMO analysis of cancer approvals
Sep 13, 2024 8:06am
ESMO: Padcev-Keytruda combo nearly doubles survival in key trial
Oct 22, 2023 10:17am
At ESMO, Merck touts Welireg's potential in kidney cancer
Oct 21, 2023 9:00am
ESMO: Searching for the perfect cup of pharma-branded espress-MO
Oct 20, 2023 7:59am
